Medical/Pharmaceuticals

Avidien Technologies Receives $4M Investment from BroadOak Capital Partners

BOSTON, Feb. 2, 2022 /PRNewswire/ -- Avidien announced today a new financing round of$4M from BroadOak Capital Partners. The investment will help Avidien expand its product roadmap, scale commercial production, and better serve research and pharmaceutical clients. Avidien CEO and Founder Rich Co...

2022-02-02 18:49 2090

Elekta increases customer focus with direct presence in Philippines

STOCKHOLM, Feb. 2, 2022 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that it has established an office inthe Philippines' capital, Manila, to offer new and existing customers superior service, education and training opportunities and faster access to the latest cancer care solutions. A dire...

2022-02-02 15:48 2196

CordenPharma Completes Acquisition of Three Manufacturing Facilities from Vifor Pharma

LUXEMBOURG, Feb. 2, 2022 /PRNewswire/ -- CordenPharma, a leading, full-service Contract Development & Manufacturing Organization (CDMO) supplying APIs, Excipients, Drug Products, and associated Packaging services, announced today the completion of the acquisition of three manufacturing facilities...

2022-02-02 11:00 2463

World's most trusted source for chemistry information, CAS, launches major biology expansion

CAS SciFinder Discovery Platform™ redefines its role in drug discovery with the inclusion of unique biosequence data collection and capabilities COLUMBUS, Ohio, Feb. 2, 2022 /PRNewswire/ -- CAS, a division of the American Chemical Society specializing in scientific information solutions, announce...

2022-02-02 10:42 2448

yoboo rewards customers with even greater savings in the 2.2 Free Shipping Sale

MANILA, Philippines, Feb. 2, 2022 /PRNewswire/ -- The "2.2 Free Shipping Sale" has just begun. From late January toFebruary 23, babies and moms can be surprised at the yoboo store through a variety of activities such as Follow & Win, Share & Win, Cashback, discounts, and platform coupons. The eve...

2022-02-02 04:51 2215

LANDMARK REDUCE LAP-HF II TRIAL DEMONSTRATES CLINICAL BENEFIT OF CORVIA® ATRIAL SHUNT IN LARGE SEGMENT OF HEART FAILURE PATIENTS

REDUCE LAP-HF II study defines treatable HFpEF patient population for atrial shunt therapy TEWKSBURY, Mass., Feb. 2, 2022 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced results from its REDUCE LAP-HF II randomized cli...

2022-02-02 01:28 1914

LANDMARK REDUCE LAP-HF II TRIAL DEMONSTRATES CLINICAL BENEFIT OF CORVIA® ATRIAL SHUNT IN LARGE SEGMENT OF HEART FAILURE PATIENTS

REDUCE LAP-HF II study defines treatable HFpEF patient population for atrial shunt therapy TEWKSBURY, Mass., Feb. 1, 2022 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced results from its REDUCE LAP-HF II randomized cli...

2022-02-01 22:50 1978

Holmusk Enters into Collaboration with Metrocare Services

NEW YORK, Feb. 1, 2022 /PRNewswire/ -- Holmusk, a leading global data science and health technology company building the world's largest real-world evidence (RWE) platform for behavioral health, has signed an agreement with Metrocare Services based inDallas, Texas on the use of real-world data to...

2022-02-01 22:00 1856

Clarity advances to cohort 2 in the SARTATE™ neuroblastoma trial

SYDNEY, Feb. 1, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has completed cohort 1 and advanced to cohort 2 in the64Cu...

2022-02-01 21:58 1306

New Business Partnership Between Otsuka Pharmaceutical and Digital Health VR Technology Developer Jolly Good

TOKYO, Feb. 1, 2022 /PRNewswire/ -- With the aim of building a regional cooperative mental health platform, Jolly Good Inc. (Chuo-ku,Tokyo; CEO: Kensuke Joji) and Otsuka Pharmaceutical Co., Ltd. (Chiyoda-ku, Tokyo; President and Representative Director:Makoto Inoue) have signed an agreement for ...

2022-02-01 21:00 1897

AMR Action Fund Appoints Scientific Advisory Board

Members will play a vital role in evaluating potential investments into clinical-stage companies developing urgently needed antibiotics BOSTON, Feb. 1, 2022 /PRNewswire/ -- The AMR Action Fund, the world's largest public-private partnership investing in the development of new antibiotics, today ...

2022-02-01 19:00 2439

Cytiva fuels biotech development in Australia and New Zealand

* VivaZome Therapeutics wins top prize with its potential to provide off-the-shelf regenerative medicines. * Part of Cytiva's BioChallenge global series, the inaugural challenge for the Australia and New Zealand region received 32 applications from various universities and companies. SYDNEY, F...

2022-02-01 07:00 2764

DEBIOPHARM AND ASPEN PARTNER TO LAUNCH PROSTATE CANCER DRUG TRELSTAR® IN SOUTH AFRICA

LAUSANNE, Switzerland and DURBAN, South Africa, Feb. 1, 2022 /PRNewswire/ -- Debiopharm (www.debiopharm.com ), a Swiss biopharmaceutical company andAspen, a South African headquartered multinational pharmaceutical company announced today their partnership to  launch Tr...

2022-02-01 06:00 2976

Denovo Biopharma LLC Announces FDA Approval of IND to Initiate First Biomarker-Guided Global CNS Clinical Trial for Treatment-Resistant Depression (TRD)

SAN DIEGO, Feb. 1, 2022 /PRNewswire/ -- Denovo Biopharma LLC ("Denovo"), a pioneer in applying precision medicine to the development of innovative therapies, today announced that the FDA has authorized the company's investigational new drug (IND) application of DB104 (liafensine) for treatment-r...

2022-02-01 05:30 2178

Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine

- NVX-CoV2373 demonstrated overall efficacy of ~90% in PREVENT-19 clinical trial conducted during the emergence of variant strains GAITHERSBURG, Md., Feb. 1, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vac...

2022-02-01 04:06 2977

Exopharm and Astellas Institute for Regenerative Medicine (AIRM) Sign Master Collaborative Services Agreement

* Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company * Initial services will seek to validate Exopharm's LEAP, LOAD and EVPS technology platforms to manufacture exosomes for Astellas, firstly at Exopharm's facili...

2022-01-31 19:00 1528

Pfizer and Alex Therapeutics announce a Strategic Commercial Partnership to provide evidence-based Digital Therapeutics to patients, starting in Germany

STOCKHOLM, Jan. 31, 2022 /PRNewswire/ -- The Stockholm-based Digital Therapeutics (DTx) company Alex Therapeutics and world leading pharmaceutical company Pfizer have joined forces to provide evidence based, clinically validated and personalized digital therapies to patients. Together, the compa...

2022-01-31 18:00 2101

Application deadline extended for Aster Guardians Global Nursing Award worth US $250,000 to 15th Feb

* Till date more than 17300+ registrations have been received from nurses from 175 countries * The announcement comes as a response to increasing requests from nurses worldwide for more time to complete the documentation process, following the Covid-19 surge * Nurses from around the world c...

2022-01-31 15:14 2468

AKESO'S LIGUFALIMAB AND IVONESCIMAB OBTAINED APPROVAL TO INITIATE A PHASE II TRIAL

HONG KONG, Jan. 30, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that the Ligufalimab (CD47 monoclonal antibody, research and development code: AK117, the novel immuno-oncology drug independently developed by the Company) and Ivonescimab (PD-1/VEGF bi-specific antibody, research and devel...

2022-01-31 10:14 2007

AKESO DOSES FIRST PATIENT IN THE PHASE III TRIAL OF IVONESCIMAB COMBINED WITH CHEMOTHERAPY IN EGFR-TKI RESISTANT EGFR MUTATION ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

HONG KONG, Jan. 30, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that the first patient was dosed in a Phase III registrational clinical trial of the Company's novel immuno-oncology drug, Ivonescimab (PD-1/VEGF bi-specific antibody, AK112), combined with chemotherapy versus placebo combin...

2022-01-31 09:51 1872
1 ... 274275276277278279280 ... 573

Week's Top Stories